	US 12,357,653 B2
	Compositions comprising circular polyribonucleotides and uses thereof
Avak Kahvejian, Lexington, MA (US); Nicholas McCartney Plugis, Cambridge, MA (US); and Alexandra Sophie De Boer, Cambridge, MA (US)
Assigned to Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Appl. No. 16/772,678
Filed by FLAGSHIP PIONEERING INNOVATIONS VI, LLC, Cambridge, MA (US)
PCT Filed Dec. 14, 2018, PCT No. PCT/US2018/065836 § 371(c)(1), (2) Date Sep. 22, 2020, PCT Pub. No. WO2019/118919, PCT Pub. Date Jun. 20, 2019.
Claims priority of provisional application 62/676,688, filed on May 25, 2018.
Claims priority of provisional application 62/599,547, filed on Dec. 15, 2017.
Prior Publication US 2020/0306286 A1, Oct. 1, 2020
Int. Cl. C07H 21/04 (2006.01); A61K 31/7088 (2006.01); C07K 7/00 (2006.01); C07K 7/06 (2006.01); C12N 15/67 (2006.01); C12P 21/00 (2006.01)

CPC A61K 31/7088 (2013.01) [C07K 7/00 (2013.01); C07K 7/06 (2013.01); C12N 15/67 (2013.01); C12P 21/00 (2013.01)]

16 Claims

1. A method of delivering a circular polyribonucleotide to a subject, comprising administering to the subject a pharmaceutical composition for expression of a first chimeric antigen receptor (CAR) and a second CAR, the pharmaceutical composition comprising:

(a) a lipid nanoparticle carrier comprising a covalently closed polyribonucleotide that comprises, in the following order:

(i) a first internal ribosome entry site (IRES);

(ii) a first expression sequence that encodes the first CAR;

(iii) a second IRES; and

(iv) a second expression sequence that encodes the second CAR; and

(b) a pharmaceutically acceptable excipient.